Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

About this update from Tenax Therapeutics, Inc.

CHAPEL HILL, N.C., May 08, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced it has awarded or will award inducement option awards between April 28, 2026 and June 1, 2026 as material inducements to the employment of four non-executive individuals newly hired by the Company in various clinical operations, medical, product development, and commercial roles. The employees received or will receive, in the aggregate, non-qualified stock options to purchase 657,500 shares of the Company's common stock with an exercise price equal to the closing price of the Company's common stock as reported by Nasdaq on the start date of each respective employee, 25% of which will vest and become exercisable on the first anniversary of the grant date, and the remaining underlying shares will vest in 36 substantially equal installments each month thereafter, subject to the employee's continued service with the Company through each applicable vesting date; collectively, the "Awards." The Awards were each approved by the Board's Compensation Committee, which is comprised solely of independent directors, as material inducements to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted outside of the Company's stockholder-approved equity incentive plan. About Tenax Therapeutics Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies. The Company owns global rights to develop and commercialize levosimendan, including TNX-103 (oral levosimendan) which it is developing for the treatment of PH-HFpEF, the most prevalent form of pulmonary hypertension globally, for which no product has been approved to date. For more information, visit www.tenaxthera.com. Tenax Therapeutics’ common stock is listed on The Nasdaq Stock Market LLC under the symbol “TENX”. Caution Regarding Forward-Looking Statements Except for historical information, all of the statements, expectations and assumptions contained in this press release are forward-looking statements. These forward-looking statements may include informati...

View stock analysis, news, and events for Tenax Therapeutics, Inc.